502.495.5040

That’s a GOOD Thing….No, Wait, That’s a BAD Thing

Aug
18

0a8448b5-8a71-4941-b876-df08b460ded3

Lower cholesterol. That’s a good thing. Everybody says so. There’s Zocor, Lipitor, Crestor, and more. There are several generics so you can get good results for about $50 per month.

Now you can get even LOWER cholesterol – by a lot. Several new drugs are ready to be released that will be much stronger and more effective in lowering cholesterol. Praluent, which is given every other week by injection, has now been approved and others are to follow.

While they effectively manage your cholesterol, they wreak havoc on your checkbook. For instance, Praluent will have a wholesale price of $1,120 for a 28-day supply. Take all your current folks who treat for high cholesterol and increase their costs by more than $12,000 per year – just for better management of their cholesterol.

Most future obstacles in controlling healthcare costs don’t involve doctors or hospitals or surgeries. They involve controlling pharmaceuticals. For every Praluent, there are 20 other drugs being developed to treat all the tough diseases like cancer, diabetes, heart disease etc. These will make the pharmaceutical industry more wealthy still and will leave you with the problem of financing them.

We have solutions, including pharmaceutical managed care organizations.

 Call us. We can do better.

William Faris, JD
Chief Executive Officer
502-495-5040
william.faris@omca.biz
www.omca.biz

Posted in Medical Cost Containment, OMCA